Author

Guocan Wang

The University of Texas MD Anderson Cancer CenterORCID 0000-0002-8922-7249Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Guocan Wang1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:chromatin & epigenetic regulation· 1 Organism:human· 1 Organism:mouse· 1 Assay:organoid / primary culture· 1 Assay:proteomics· 1

Frequent Co-Authors

Binkui LiiD· 1 shared C. Li· 1 shared Dinglan ZuoiD· 1 shared Emily Zhao· 1 shared Gengyi ZouiD· 1 shared Guang PengiD· 1 shared Jaffer A. AjaniiD· 1 shared Jiliang QiuiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Binkui LiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ARID1A deficiency unleashes centromeric RNA transcription to drive chromosomal instability and boosts PKMYT1 inhibitor efficacy via RNA sensing

C. Li, Xueqian Cheng, Wiezhen Liu, Gengyi Zou, Thi Hong Minh Nguyen, Emily Zhao, Noemi Ira, Liyong Zeng, Yibo Fan, Shilpa S. Dhar, Guocan Wang, Shumei Song, Ming Zhao, Rugang Zhang, Yuan‐Hung Lo, , Guang Peng

This study shows that ARID1A deficiency increases centromeric RNA transcription, causing chromosomal instability and enhancing the effectiveness of PKMYT1 inhibitors through RNA sensing.

bioRxiv · Apr 13, 2026 · PreprintCancer Biology

Targeting PRMT3 Impairs Methylation and Oligomerization of HSP60 to Boost Anti-Tumor Immunity by Activating cGAS/STING Signaling

Yunxing Shi, Zongfeng Wu, Shaoru Liu, Dinglan Zuo, Yi Niu, Yuxiong Qiu, Liang Qiao, Wei A. He, Jiliang Qiu, Yunfei Yuan, Guocan Wang, Binkui Li

This study identifies PRMT3 as a driver of immunotherapy resistance in HCC, showing that targeting it enhances anti-tumor immunity via cGAS/STING activation.

Nature Communications · Sep 10, 2024Peer-reviewedCancer Biology